![](/img/cover-not-exists.png)
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification
Mazzotta, M., Filetti, M., Rossi, A., Roberto, M., Occhipinti, M., Pernazza, A., Di Napoli, A., Scarpino, S., Vecchione, A., Giusti, R., Marchetti, P.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2019.11.016
Date:
March, 2020
File:
PDF, 801 KB
2020